Séminaires CRCL-CLB

Séminaires CRCL-CLB

Séminaire médico-scientifique CRCL/CLB


Le prochain séminaire médico-scientifique CRCL/CLB se tiendra le vendredi 3 mars à 11h30 dans la salle ONCORA (Centre Léon Bérard, 2e étage). Nous serons heureux d'accueillir Silvia Giodarno (Turino). Plus d'informations prochainement.


Evènements scientifiques - 2017

Evènements scientifiques - 2017

Save the date :
4th ANRS HBV Cure Workshop
May 16th 2017 - Espace Saint-Martin - 75003 Paris -
Preliminary program click here

Le 3e Symposium CRCL 2017 vous donne rendez-vous les 25-27 septembre 2017 ! Découvrez le nouveau site web dédié en cliquant ici.




MANY THANKS !
The 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology) took place recently in Lyon. It was a great pleaser to welcome 20 international speakers as well as a total of 380 participants! We thank our sponsors and partners which help us to organize this event! Many thanks again.
We can still access to the final program: click here


Autres actualités

Janvier 2017
Communiqué de presse : SANOFI-INSERM HBV Cure program: a medical, academic and pharmaceutical alliance for research on Hepatitis B. Cliquez ici

Création d'un Laboratoire International Associé (LIA) entre l'équipe CRCL d'Alain Puisieux "EMT et plasticité des cellules cancéreuses" et l'équipe de  Frédéric Hollande "Molecular Mechanisms of Tumour Progression" du Victorian Comprehensive Cancer Centre (Université de Melbourne, Australie).
Offres d'emploi

Offres d'emploi

Plusieurs postes sont à pourvoir au CRCL : cliquez ici

LATEST NEWS

January 2017

Postdoc in tumor immunology: click here
Poste d'IE
(CDD 2 ans) en immuno-oncologie : cliquez ici
Postdoc
in the G. Ichim's team : click here
Stage M2 Recherche en Immuno-oncologie (profil recherché : Interne en Anatomopathologie) : cliquez ici (réponse avant le 15/01)
December 2016
A postdoc position
in the team of F. Zoulim : click here
November 2016
- poste d'ingénieur d'étude ou AI en immunomarquage : cliquez ici
Other positions
- A Computational Biologist/Immunology position is available in the team of C. Caux and JY Blay. click here

- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here

Suivez-nous sur Twitter !

Suivez les actualités du CRCL sur notre compte Twitter !
Informations scientifiques

Informations scientifiques

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors

mardi 22 mars 2016
This work involved the team of Alain Puisieux.
Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
PubMed access: click here

Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers

vendredi 25 mars 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here

Vidéo Equipe I Chemin/P Merle